Groupe la Francaise Has $3.68 Million Stake in Stryker Corporation $SYK

Key Points

• Groupe la Francaise increased its stake in Stryker Corporation by 138% in Q1, acquiring an additional 5,802 shares, bringing its total holdings to 10,007 shares valued at approximately $3.68 million.
• Multiple institutional investors have significantly raised their stakes in Stryker, with GAMMA Investing LLC increasing its position by an astonishing 43,226.8%, owning over 2 million shares now worth around $772 million.
• Stryker's most recent quarterly earnings report surpassed expectations, with an EPS of $3.13, compared to an estimate of $3.07, and the company has announced a quarterly dividend of $0.84 per share.

Groupe la Francaise raised its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 138.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,007 shares of the medical technology company's stock after buying an additional 5,802 shares during the period. Groupe la Francaise's holdings in Stryker were worth $3,678,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Elefante Mark B purchased a new stake in shares of Stryker during the fourth quarter valued at approximately $337,000. Mogy Joel R Investment Counsel Inc. raised its stake in shares of Stryker by 3.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock valued at $36,561,000 after purchasing an additional 3,218 shares during the period. Ferguson Wellman Capital Management Inc. raised its stake in shares of Stryker by 1.9% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock valued at $65,096,000 after purchasing an additional 3,341 shares during the period. Harbor Capital Advisors Inc. purchased a new stake in shares of Stryker during the first quarter valued at approximately $1,840,000. Finally, Mar Vista Investment Partners LLC raised its stake in shares of Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock valued at $33,572,000 after purchasing an additional 8,353 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

SYK stock traded down $3.43 during trading on Thursday, hitting $389.73. 862,944 shares of the company's stock traded hands, compared to its average volume of 1,417,868. The stock has a fifty day moving average price of $388.61 and a two-hundred day moving average price of $379.45. The stock has a market capitalization of $148.99 billion, a price-to-earnings ratio of 51.62, a price-to-earnings-growth ratio of 2.87 and a beta of 0.91. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company's quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio is currently 44.50%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Viju Menon sold 500 shares of the stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of analyst reports. Needham & Company LLC lifted their price objective on shares of Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Roth Mkm lifted their price target on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen upgraded shares of Stryker from a "hold" rating to a "buy" rating in a research note on Friday, July 18th. Truist Financial set a $415.00 price target on shares of Stryker and gave the stock a "hold" rating in a research note on Monday, August 4th. Finally, Evercore ISI lifted their price target on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Fifteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $430.10.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.